His net worth soared by 500 billion to become Asia's new richest man, and there is a bigger business hidden in his family!
His being the richest man is also a symbol of wealth growth returning to the real world.
Wenhua Business Strategy丨Zhou Ruihua
The book wealth increased by more than US$70 billion in one year, and the richest man in China and the richest man in Asia were made.
The 66-year-old Zhong Suansui relied on his own definition of "tea eggs" to rewrite the ranking of the top rich, but his bigger industry and wealth to watch, or another big-scale war he called the "atomic bomb" .
On the last day of 2003, the famous singer Anita Mui died of cervical cancer, and the "female killer" cervical cancer became an unprecedented fever.
Just one year before the death of Anita Mui, a biotechnology company named "Xiamen Wantai Canghai" (hereinafter referred to as Wantai Bio/Wandai), has quietly launched a bivalent HPV vaccine specifically for cervical cancer (drug name: Xin Kening) R&D.
Standing behind Wantai Biotech is the new richest man in Asia, Zhong Suisui.
Zhong Sui Sui, who has been a media person, always hides himself from the public after starting a business. He seldom shows up, but when he shows up, it is often a big business war. He even uses his own power as an enemy to the entire industry. Some people call him a "lone wolf".
When "Lone Wolf" spoke, he wanted to do something big.
The bivalent HPV vaccine is by far the largest incident by Zhong Sui Sui outside of Nongfu Spring, but at the time, the outside world was almost unaware of this incident. Its starting point is also quite low.
In 2001, the Yangshengtang controlled by Zhong Suisuan purchased a 95% stake in Wantai Biotech from a Hong Kong company for 17.1 million yuan. Wantai was already engaged in in vitro diagnostic reagents and vaccines business, but there were no bright spots in R&D and performance.
Zhong Suansui's goal is to jump into the new field of vaccine business and make it solid and stronger.
Zhong Sui Sui, who already owns the "cash cow" national-level fast-moving consumer brand Nongfu Spring, believes that he has the qualifications to challenge higher goals, and must cultivate new growth poles and competition for the company's longer-term and higher-position development force.
The vaccine industry has high barriers, a long research and development cycle, and high risks, but it also benefits: once a technical barrier is built, it will be difficult for latecomers to catch up. It is an ideal target. From "selling water" to vaccine research and development, the crossover is a bit big, but in terms of making a fuss about "health" since his founding, this crossover is not super-class.
In 2002, Zhong Suansui, who opened his eyes to find a breakthrough in the vaccine, learned that the HPV vaccine from GlaxoSmithKline (GSK) and Merck & Co., Ltd. in the United Kingdom had entered the third clinical phase, and the pharmaceutical giants had already verified the technical feasibility of the HPV vaccine. , HPV vaccine will make a big difference.
▲ Merck's Jiadaxiu quadrivalent HPV vaccine
After some investigations, Zhong Suisui decided to use HPV vaccine as the starting point for realizing and strengthening Wantai vaccine business.
HPV vaccines are genetically modified vaccines, which require targeted insertion of DNA into the vector for full expression. At that time, GSK and Merck’s insect cells and Saccharomyces cerevisiae vectors were very mature, and a variety of genetically modified vaccines were developed, and the production system was also very complete.
Wantai therefore faces two choices:
The first is ethics, using the mature patented technology of pharmaceutical giants, using insect cells or Saccharomyces cerevisiae as carriers, which can save R&D investment and time, but it also means permanent payment of commercial licensing fees close to astronomical figures;
The second is self-reliance, bypassing the patent barriers of giants, starting from scratch, and independent research and development. This requires a huge investment risk, including time costs, but the advantage is that once it succeeds, it will be truly independent and is expected to fill the gap in China as an original.
Zhong Suansui's final decision is to do it himself—
In cooperation with the R&D team of Xiamen University, we started from scratch to develop the Chinese own HPV vaccine.
Although he knows that there are tigers in the mountains, he is inclined to travel to the mountains, but the difficulty is beyond imagination:
It took 5 years to overcome countless difficulties and experience countless failures. In 2007, Wantai developed the vaccine candidate Xinkening.
In 2010, Xinkening, who had been waiting for the approval for three years, finally got the clinical approval and entered the clinical stage.
Wait three years for an approved document, but this is the beginning of the inspection results.
In 2012, Xinkening, which has been working for a full 10 years, entered the Phase III clinical trial.
In 2017, the third phase of clinical trials ended. Zhong Sui Sui, who was 48 years old to 63 years old, finally waited for the good news. The five-year follow-up results of the immune effects and side effects of more than 7,000 volunteers showed:
In terms of the prevention of precancerous lesions and persistent HPV infection, the two key effect indicators, Xinkening has a protection rate of 100% for the corresponding high-grade precancerous lesions and a protection rate of 97.8% for HPV persistent infection.
This also means that, regardless of safety or preventive effects, Wantai's Xinkening does not lose imported vaccines.
After another two years of waiting, on December 31, 2019, Zhong Sui Sui waited for the best New Year gift in his life.
On the same day, the official website of the National Medical Products Administration finally posted the news that "the first domestic recombinant human papillomavirus vaccine was approved for marketing."
So far, he has been suffering for 18 years.
Wantai came up with the news of an explosive achievement, and it gradually surfaced.
The rise of Nongfu Spring has given Zhong Sui Sui the impression that he is good at marketing and hype. Some even ridiculed that Nongfu Spring is an advertising company. Zhong Suansui did not shy away from this: "If a company does not hype, it is a mummy."
But in Wantai Biology, he has hidden for 18 years.
Zhong Sui Sui, who emphasized that enterprises must hype, is unceremonious about what should be hype, and what should not be hype is unwavering. "The enterprise is not hype, it is a mummy." In addition, he has the next sentence:
"Technical innovation can compete, and marketing without technology will only die faster."
In 1983, a well-known German scientist, Harald zur Hausen, found HPV (human papiloma virus) in cervical cancer samples, and "figured out" this cause of cervical cancer. The "culprit" of malignant tumors.
Globally, cervical cancer is the fourth most common cancer in women after breast, colorectal and lung cancer. There are 530,000 cases of invasive cervical cancer and 260,000 deaths every year. It is a true female health killer.
After HPV was discovered, the scientific community had a guess: Since cervical cancer is caused by a virus, can it be prevented by a vaccine?
Along this line of thinking, the scientific community has begun a relay race to develop HPV vaccines.